Intrinsiqq
Lite Strategy, Inc. logo

Lite Strategy, Inc. Financials

LITS

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 17 available years
Income Statement
TTM
JUN 2026
~5.2:1 split
JUN 2025
JUN 2024
JUN 2023
JUN 2022
Revenues
Revenue$0–$0$65$49$41
Cost of Revenue$0$54$0$11$0$0
Gross Profit$0–$0$54$49$41
General & Administrative$14$12$14$23$33$31
Research & Development$4$0$4$17$52$86
Total Operating Expenses$17$67$17$51$86$116
Operating Income-$17-$67-$17$15-$37-$75
Non-Operating
Net Interest Expense$1$0$1$3$3$0
Other Non-Operating Income (Expense)$2-$5$0-$0$2$21
EBT (Earnings Before Tax)–-$71-$16$18-$32-$54
Income Tax Expense–$0$0$0$0$0
Net Income
Net Income-$16-$71-$16$18-$32-$54
Per Share Data
Revenue Per Share$0.00–$0.00$9.80$7.33$6.50
EPS (Basic)-$2.39-$2.06-$2.39$2.67-$4.78-$8.75
EPS (Diluted)-$2.39-$2.06-$2.39$2.67-$4.78-$9.99
Weighted Avg Shares (Basic)6.7M34.6M6.7M6.7M6.7M124.5M
Weighted Avg Shares (Diluted)6.7M34.6M6.7M6.7M6.7M125.1M
Shares Outstanding6.7M34.6M6.7M6.7M6.7M6.3M
Dividends Per Share––$0.00$1.75$0.00–

Lite Strategy (LITS) financials: revenue, profit and margins

Lite Strategy (LITS) generated about n/a in revenue and -$71 million in net income over the trailing twelve months, growing at roughly 67.8% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Lite Strategy profitable?+

Lite Strategy reported about -$71 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Lite Strategy growing?+

Lite Strategy's revenue has compounded at roughly 67.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside LITS's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 22 Sept 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 29 Sept 2026. How this is calculated.

Fiscal year ends Jun.

Peers

Pharmaceutical Preparations · Pick stocks to compare with LITS

CompareIntrinsic value
ENTAEnanta Pharmaceuticals Inc.
$10.65+2.70%25
ABCLAbCellera Biologics Inc.
$12.28+0.82%10
XLOXilio Therapeutics, Inc.
$8.71+0.35%40
CYTKCytokinetics, Incorporated
$63.60+2.07%10
DERMJourney Medical Corp
$4.73+1.94%25
FBIOFortress Biotech Inc.
$1.97+1.55%59
RMTIRockwell Medical, Inc.
$8.05-0.49%37
BCYCBicycle Therapeutics PLC
$3.72+1.36%40

Spot a number that looks wrong? Check it in LITS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LITS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.